Serological identification of fast progressors of structural damage with rheumatoid arthritis

@inproceedings{Siebuhr2013SerologicalIO,
  title={Serological identification of fast progressors of structural damage with rheumatoid arthritis},
  author={Anne Sofie Siebuhr and Anne-C Bay-Jensen and Diana Julie Leeming and Adam Plat and Inger Byrjalsen and Claus Christiansen and D{\'e}sir{\'e}e van de Heijde and Morten Asser Karsdal},
  booktitle={Arthritis Research & Therapy},
  year={2013}
}
IntroductionRheumatoid arthritis (RA) patients with structural progression are in most need of immediate treatment to maintain tissue integrity. The serum protein fingerprint, type I collagen degradation mediated by matrix metalloproteinases (MMP)-cleavage (C1M), is a biomarker of tissue destruction. We investigated whether baseline serum C1M levels could identify structural progressors and if the biomarker levels changed during anti-inflammatory treatment with tocilizumab (TCZ).MethodsThe… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 29 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M).

  • Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • 2011
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

BayJensen AC: Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers–are they the cause or the consequence of the disease

MA Karsdal, K Henriksen, DJ Leeming, T Woodworth, E Vassiliadis
  • Clin Biochem
  • 2010
VIEW 2 EXCERPTS

Similar Papers